Caribou Biosciences’ 2025 outlook aimed for key trial readouts for two cancer cell therapies in the first half of the year and the start of clinical testing in an autoimmune disease. The CRISPR ...

Caribou Biosciences is winnowing down for the second time in the last year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates. The ...

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the execution of an exclusive license agreement with ...

Last year, AbbVie decided to walk away from a pact with gene editing biotech Editas that was originally penned via its new buyout, Allergan. Now, the Big Pharma is back in the CRISPR biotech game, ...

Caribou is a clinical-stage biotech that specializes in CRISPR gene-editing therapies. Caribou said it had $291 million in cash at the end of the first quarter. The company has a pipeline that ...